Dr. Reddy’s Laboratories Ltd. has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. granting Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of the drug. Dr. Reddy’s will be responsible for manufacturing scale up and obtaining regulatory approval for marketing of the drug in respective countries.

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. FDA to treat Covid-19.